Information Provided By:
Fly News Breaks for June 11, 2015
RIG, RDC, PTBI, PACD, TIS, ORIG, NE, LBY, MHK, HOS, HZNP, AWAY, HLT, FRPT, FI, ESV, SSP, DO, BRS, DEPO, ATW, AGEN
Jun 11, 2015 | 10:00 EDT
Today's noteworthy initiations include: Agenus (AGEN) initiated with an Outperform at Oppenheimer... Atwood Oceanics (ATW) initiated with an Equal Weight at Barclays... Bristow Group (BRS) initiated with an Equal Weight at Barclays... Depomed (DEPO) initiated with an Equal Weight at Morgan Stanley... Diamond Offshore (DO) initiated with an Underweight at Barclays... E.W. Scripps (SSP) initiated with an Outperform at Wells Fargo... Ensco (ESV) initiated with an Equal Weight at Barclays... Frank's International (FI) initiated with an Equal Weight at Barclays... Freshpet (FRPT) initiated with a Perform at Oppenheimer... Hilton (HLT) initiated with a Buy at Brean Capital... HomeAway (AWAY) initiated with an Overweight at Stephens... Horizon Pharma (HZNP) initiated with an Overweight at Morgan Stanley... Hornbeck Offshore (HOS) initiated with an Overweight at Barclays... Libbey (LBY) initiated with an Overweight at Piper Jaffray... Mohawk (MHK) initiated with a Hold at Cantor... Noble Corp. (NE) initiated with an Underweight at Barclays... Ocean Rig UDW (ORIG) initiated with an Underweight at Barclays... Orchids Paper (TIS) initiated with a Buy at Craig-Hallum... Pacific Drilling (PACD) initiated with an Equal Weight at Barclays... PlasmaTech (PTBI) initiated with a Buy at Roth Capital... Rowan Companies (RDC) initiated with an Equal Weight at Barclays... Transocean (RIG) initiated with an Underweight at Barclays.
News For AGEN;ATW;DEPO;BRS;DO;SSP;ESV;FI;FRPT;HLT;AWAY;HZNP;HOS;MHK;LBY;NE;ORIG;TIS;PACD;PTBI;RDC;RIG From the Last 2 Days
AGEN
Mar 18, 2024 | 08:52 EDT
B. Riley analyst Mayank Mamtani lowered the firm's price target on Agenus to $5 from $6 and keeps a Buy rating on the shares. The company's Q4 earnings focused on the roadmap to BOT/BAL U.S. and EU accelerated approval submission, with management reiterating their bullish view on BOT/BAL in terms of efficacy, safety, and commercial opportunity, the analyst tells investors in a research note.